Each week we present you with the latest featured study from the research teams at JAMA, Journal of the American Medical Association. Check out the video for intriguing…
Each week we present you with the latest featured study from the research teams at JAMA, Journal of the American Medical Association. Check out the video for intriguing…
NEW YORK (Reuters Health) – Propranolol is a safe treatment for severe infantile hemangiomas that can markedly shorten the disease course, according to findings from a small study…
NEW YORK (Reuters Health) – Therapy with denosumab appears to augment bone mineral density and lower the risk of fracture among men with prostate cancer undergoing androgen-deprivation therapy,…
NEW YORK (Reuters Health) – As first-line therapy for advanced chronic lymphocytic leukemia, bendamustine produced significantly higher response rates and longer progression-free survival than chlorambucil in a phase…
NEW YORK (Reuters Health) – Both progression-free and overall survival are extended in patients with advanced non-small cell lung cancer treated with erlotinib following standard chemotherapy, according to…
NEW YORK (Reuters Health) – Use of metformin is associated with a decreased risk of pancreatic cancer in patients with diabetes, new research shows. By contrast, treatment with…
NEW YORK (Reuters Health) – In trials of antimuscarinic agents for overactive bladder, the placebo responses tend to be large, statistically significant, and heterogeneous, according to a meta-analysis…
Adele Viguera, MD, MPH, Assistant Professor of Psychiatry, Director of Clinical Research, Center for Women’s Mental Health, Cleveland Clinic, discusses lithium use in pregnancy, one of the oldest…
NEW YORK (Reuters Health) – Upon starting an antipsychotic drugs, older patients with diabetes are prone to episodes of hyperglycemia severe enough to require hospitalization, Canadian researchers report…
NEW YORK (Reuters Health) – Nearly one out of six patients in China who is prescribed an antihypertensive agent will discontinue treatment within 6 months. Multiple factors affect…
NEW YORK (Reuters Health) – In patients with metastatic renal cell carcinoma, first-line treatment with interferon (IFN)-alpha plus sunitinib or bevacizumab has “clinically relevant and statistically significant” survival…
